Form 4: Thermo Fisher EVP Sells Shares Under 10b5-1 Plan

Thermo Fisher Scientific Executive Vice President Gianluca Pettiti sold 400 shares of common stock for $541.20 per share under a pre-arranged trading plan.

Summary

• Gianluca Pettiti, Executive Vice President of Thermo Fisher Scientific Inc. (TMO), reported a sale of company common stock.
• The transaction involved the disposition of 400 shares of common stock.
• The shares were sold at a price of $541.20 per share, totaling $216,480.
• This sale was executed on February 9, 2026.
• The transaction was conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Pettiti on September 12, 2025.
• Following this transaction, Mr. Pettiti directly beneficially owns 20,752.223 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a pre-scheduled transaction under a Rule 10b5-1 plan, which typically does not signal a change in management's outlook on the company's fundamentals.

Positives

• The sale was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than a discretionary sale based on new, non-public information.

Negatives

• An Executive Vice President sold 400 shares of company common stock.

Risks

• Insider sales, even when pre-planned, can sometimes be interpreted by the market as a minor negative signal regarding future company prospects, though the Rule 10b5-1 plan mitigates this perception.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common practice for executives to diversify holdings or manage liquidity without implying a negative outlook on the company's future performance. This is a standard mechanism used across various industries to avoid accusations of insider trading.

Stakeholder Impact

• Shareholders: May observe a minor dilution of insider ownership, but the pre-arranged 10b5-1 plan mitigates concerns about discretionary selling based on new information.

Key Dates

Recommendation

The filing reports a routine, pre-scheduled insider sale under a 10b5-1 plan. This type of transaction is common for executives managing personal finances and typically does not reflect a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this report.

Keywords

Thermo Fisher Scientific, TMO, Insider Sale, Form 4, Gianluca Pettiti, Executive Vice President, 10b5-1 Plan, Stock Transaction